Citius Pharmaceuticals Inc (NASDAQ: CTXR) recorded a lighter trading session with 0.51 million shares exchanged, falling below its average daily volume of 0.74 million. The Biotechnology firm, operating within the Healthcare sector, hit a session high of $1.37 and a low of $1.23.
Over the past 52 weeks, CTXR stock has fluctuated between a high of $12.84 and a low of $0.65, highlighting its volatile nature. The company currently has a 1-year price target of $6.00 and a beta of 1.52, signaling higher volatility compared to the market average.
Price Performance and Earnings
Stock performance serves as a key indicator for investors assessing potential returns. Citius Pharmaceuticals has experienced considerable volatility recently. Over the past week, CTXR declined -21.02%, and it fell -3.50% over the past month. However, it showed modest improvement over three months with a 0.81% gain and rose 77.40% over six months.
Despite those short-term gains, CTXR lost -69.00% year-over-year and has dropped -85.79% year-to-date, reflecting investor caution amid biotech market headwinds.
The company’s trailing 12-month EPS stands at -4.96, while analysts expect next year’s EPS to reach 0.37, indicating a potential turnaround. The next-quarter EPS estimate is -0.43, implying an EPS growth rate of 50.34% for this year and 112.48% for next year, signaling optimism about a recovery in earnings.
Float and Short Interest
Currently, Citius Pharmaceuticals has 18.47 million shares outstanding, with 17.98 million shares available for trading. As of October 15, 2025, short interest totaled 1.58 million shares, indicating modest bearish sentiment.
The company’s leadership team includes Leonard L. Mazur, Co-Founder, CEO, Chairman & Secretary, and Myron Z. Holubiak, Co-Founder & Executive Vice Chairman — both of whom have played key roles in the company’s strategic direction.
Recent Financial Overview
In its most recent fiscal quarter ending June 30, 2025, CTXR reported no revenue, consistent with early-stage biotech operations still in the development phase. Operating income was – $8.79 million, with an EBITDA of -$8.73 million and diluted EPS of -$0.80, underscoring the company’s ongoing investment in research and clinical trials.
Analysts’ Ratings and Price Targets
Currently, one analyst covers Citius Pharmaceuticals Inc, maintaining a “Buy” rating with no “Sell” or “Hold” recommendations. The average 12-month price target stands at $6.00, with both the high and low targets set at the same level.
This indicates that analysts expect a substantial upside — a potential 383.87% increase from current levels — suggesting strong optimism about CTXR’s long-term prospects if key milestones are achieved.
EPS: Estimates vs. Actual
Analysts project annual EPS estimates ranging from -6.61 (low) to -4.83 (high), with an average of -5.72. The company’s previous quarter posted an earnings surprise of $0.11, reflecting better-than-expected results despite the losses.
Looking ahead, next-quarter EPS is expected to average -0.30, with both high and low estimates aligned at the same figure, pointing to stability in near-term expectations.
Overall, Citius Pharmaceuticals Inc (NASDAQ: CTXR) remains a high-risk, high-reward biotech play. While short-term volatility persists and revenues remain absent, analysts see significant upside potential driven by future pipeline progress and improved earnings outlook.